Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients

Clinical Endocrinology

Volumn 80, Issue 2, 2014, Pages 228-234

  Xiang, Guangda ^a   Zhang, Junxia ^a   Ling, Yue ^a   Zhao, Linshuang ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AEROBIC EXERCISE; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; BODY MASS; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; FLOW MEDIATED ARTERY DILALATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BLOOD GLUCOSE; BRACHIAL ARTERY; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME;

EID: 84891848583     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12312     Document Type: Article

References (36)

1. Zauli, G., &, Secchiero, P., (2006) The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine & Growth Factor Reviews, 17, 245-257. (Pubitemid 44038614)
2. Mariani, S.M., &, Krammer, P.H., (1998) Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte. European Journal of Immunology, 28, 973-982. (Pubitemid 28116210)
3. Secchiero, P., Gonelli, A., Carnevale, E., et al,. (2003) TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and Erk pathway. Circulation, 107, 2250-2256. (Pubitemid 36547221)
4. Almasan, A., &, Ashkenazi, A., (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine & Growth Factor Reviews, 14, 337-348. (Pubitemid 36693152)
5. Li, J.H., Kirkiles-Smith, N.C., McNiff, J.M., et al,. (2003) TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. Journal of Immunology, 171, 1526-1533. (Pubitemid 36900088)
6. O'Brien, L.A., Richardson, M.A., Mehrbod, S.F., et al,. (2007) Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an EPCR- independent mechanism involving Egr-1/Erk-1/2 activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 2634-2641. (Pubitemid 350158916)
7. Simoncini, S., Njock, M.S., Robert, S., et al,. (2009) TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation. Circulation Research, 104, 943-951.
8. Schoppet, M., Sattler, A.M., Schaefer, J.R., et al,. (2006) Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis, 184, 446-447. (Pubitemid 43049733)
9. Secchiero, P., Corallini, F., Ceconi, C., et al,. (2009) Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS ONE, 4, e4442.
10. Niessner, A., Hohensinner, P.J., Rychli, K., et al,. (2009) Prognostic value of apoptosis markers in advanced heart failure patients. European Heart Journal, 30, 789-796.
11. Volpato, S., Ferrucci, L., Secchiero, P., et al,. (2011) Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis, 215, 452-458.
12. Boneti, P.O., Lerman, L.O., &, Lerman, A., (2003) Endothelial dysfunction, a marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 168-175. (Pubitemid 36231924)
13. Xiang, G.D., Xu, L., Zhao, L.S., et al,. (2006) The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes, 55, 2126-2131. (Pubitemid 44509988)
14. Xiang, G.D., &, Wu, Y.H., (2003) Apolipoprotein e4 allele and endothelium- dependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia, 46, 514-519.
15. Xiang, G.D., &, Wang, Y.L., (2004) Regular aerobic exercise training improves endothelium-dependent artery dilation in patients with impaired fasting glucose. Diabetes Care, 27, 801-802.
16. Brombo, G., Volpato, S., Secchiero, P., et al,. (2013) Association of soluble Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with central adiposity and low-density lipoprotein cholesterol. PLoS ONE, 8, e58225.
17. Secchiero, P., Candido, R., Corallini, F., et al,. (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation, 114, 1522-1530. (Pubitemid 44527008)
18. Zauli, G., Toffoli, B., di Iasio, M.G., et al,. (2010) Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes, 59, 1261-1265.
19. Di Bartolo, B.A., Chan, J., Bennett, M.R., et al,. (2011) TNF-related apoptosis inducing ligand (TRAIL) protects against diabetes and atherosclerosis in ApoE-/-mice. Diabetologia, 54, 3157-3167.
20. Bernardi, S., Zauli, G., Tikellis, C., et al,. (2012) TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. Clinical Science (Lond), 123, 547-555.
21. Bisgin, A., Yalcin, A.D., &, Gorczynski, R.M., (2012) Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients. Diabetes Research and Clinical Practice, 96, e84-e86.
22. Kawano, N., Mori, K., Emoto, M., et al,. (2011) Association of serum TRAIL levels with atherosclerosis in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 91, 316-320.
23. Park, S.M., Schickel, R., &, Peter, M.E., (2005) Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Current Opinion in Cell Biology, 17, 1-7.
24. Pan, G., Ni, J., Wei, Y.F., et al,. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277, 815-818. (Pubitemid 27366732)
25. Zhang, X.D., Nguyen, T., Thomas, W.D., et al,. (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Letters, 483, 193-199.
26. Secchiero, P., Zerbinati, C., Rimondi, E., et al,. (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cellular and Molecular Life Sciences, 61, 1965-1974. (Pubitemid 39094803)
27. Zauli, G., Pandolfi, A., Gonelli, A., et al,. (2003) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially up-regulates nitric oxide and prostanoid production in primary human endothelial cells. Circulation Research, 92, 732-740. (Pubitemid 36457637)
28. Wannamethee, S.G., Shaper, A.G., Lowe, G.D., et al,. (2006) Renal function and cardiovascular mortality in elderly men: the role of inflammatory, procoagulant, and endothelial biomarkers. European Heart Journal, 27, 2975-2981. (Pubitemid 44950441)
29. Ferri, C., Croce, G., Cofini, V., et al,. (2007) C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis. Current Pharmaceutical Design, 13, 1631-1645. (Pubitemid 46979719)
30. Muniyappa, R., &, Sowers, J.R., (2013) Role of insulin resistance in endothelial dysfunction. Reviews in Endocrine & Metabolic Disorders, 14, 5-12.
31. Xiang, G.D., Pu, J.H., Zhao, L.S., et al,. (2009) Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes. Diabetic Medicine, 26, 397-403.
32. Beer, S., Feihl, F., Ruiz, J., et al,. (2008) Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes. Vascular Health and Risk Management, 4, 1449-1458.
33. Eriksson, A., Attvall, S., Bonnier, M., et al,. (2007) Short-term effects of metformin in type 2 diabetes. Diabetes, Obesity & Metabolism, 9, 330-336. (Pubitemid 46502051)
34. Bailey, C.J., (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovascular Drugs and Therapy, 22, 215-224.
35. Topcu, S., Tok, D., Caliskan, M., et al,. (2006) Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. Clinical Endocrinology (Oxf), 65, 75-80.
36. Weng, J., Li, Y., Xu, W., et al,. (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet, 371, 1753-1760. (Pubitemid 351697950)